FDA approves Jelmyto (mitomycin gel) for treatment of low-grade upper tract urothelial cancer (UTUC).

UTUC corresponds to a subset of urothelial cancers that arise in the lining of the kidney or the ureter. The approval was based on a trial (n=71) which reported a complete response at 3 months in 41 patients (58%) following six treatments of the gel administered weekly.


US Food and Drug Administration